Generate Biomedicines (GENB) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Xeris Biopharma is the larger company by market cap ($1.91 billion vs $1.84 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GENB | XERS |
|---|---|---|
| Share price | $14.34 | $10.48 |
| Market cap | $1.84B | $1.91B |
| 1-day change | +2.50% | +2.85% |
| YTD return | — | +33.50% |
| 1-year return | — | +27.96% |
| 5-year return | — | +424.00% |
| Forward P/E | — | 28.32 |
| EPS (TTM) | $-2.44 | $-0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $291.85M |
| Revenue growth (YoY) | — | +43.72% |
| Net income (latest FY) | — | $554.00K |
| Gross margin | — | 85.41% |
| Operating margin | — | 8.53% |
| Net margin | — | 0.19% |
| 52-week high | $22.67 | $11.33 |
| 52-week low | $11.00 | $5.25 |
| Distance from 52-week high | -36.74% | -7.50% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +88.28% | +22.71% |
| Average volume | 1.05M | 2.17M |
| Shares outstanding | 128.35M | 182.32M |
| Employees | 312 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Generate Biomedicines
GENB stock →Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 312 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
GENB vs XERS FAQ
Which is bigger, Generate Biomedicines or Xeris Biopharma?
Xeris Biopharma (XERS) is larger, with a market capitalization of $1.91B compared with $1.84B for Generate Biomedicines (GENB).
Are Generate Biomedicines and Xeris Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.